mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response

European Radiology

Volumn 26, Issue 1, 2016, Pages 278-285

  Lamuraglia, M ^c   Raslan, S ^b   Elaidi, R ^a   Oudard, S ^a   Escudier, B ^d   Slimane, K ^e   Penna, R Renard ^b   Wagner, M ^b   Lucidarme, O ^b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e NOVARTIS PHARMA K K   (Japan)

Author keywords

3D imaging; Computed tomography; Neoplasm metastasis; Renal cell carcinoma; Tumour response

Indexed keywords

EVEROLIMUS; PLACEBO; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER SURVIVAL; CHOI CRITERIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY METASTASIS; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL RATE; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FRANCE; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EVEROLIMUS; FEMALE; FRANCE; HUMANS; IMAGING, THREE-DIMENSIONAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84948715371     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-015-3828-7     Document Type: Article

References (15)

1. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
2. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759
3. Smith AD, Shah SN, Rini BI et al (2010) Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194:1470–1478
4. Schmidt N, Hess V, Zumbrunn T et al (2013) Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 23:632–639
5. Van der Veldt M, Meijerink MR, van den Eertwegh JM et al (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102:803–809
6. Krajewski KM, Guo M, Van den Abbeele AD et al (2011) Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell cancer. Eur Urol 59:856–862
7. Nathan PD, Vinayan A, Stott D et al (2010) CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9:15–19
8. Krajewski KM, Franchetti Y, Nishino M et al (2014) 10 % Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist 19:507–514
9. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456
10. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265
11. Oudard S, Thiam R, Fournier LS et al (2012) Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer 48:1512–1518
12. Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
13. Stacchiotti S, Verderio P, Messina A et al (2012) Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 118:5857–5866
14. Liu K, Li G, Fan C et al (2012) Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 53:127–134
15. Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194:157–165